SavedAdd your journal

Journals / Turkish Journal of Hematology / 2008 / Cilt: 25 - Sayı: 2

Akut myeloblastik lösemide (AML) allojeneik hematopoetik kök hücre transplantasyonu (Allo-HKHT): Tek merkez deneyimi

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloblastic leukemia (AML): A single center experience

Osman İLHAN
Pervin TOPÇUOĞLU
Murat ARAT
Ender A. SOYDAN
Meltem K. YÜKSEL
Önder ARSLAN
Muhit ÖZCAN
Günhan GÜRMAN
TANER DEMİRER
Hamdi AKAN
Nahide KONUK
Akın UYSAL
Pages
87–93
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Estimated leukemia-free survival (LFS) and overall survival (OS) at 10 years were 43.4%±5.2% and 52.7%±4.6%, respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: We retrospectively analyzed the impact of pre- and post-transplant variables on the outcome of transplanta¬tion in 145 consecutive patients with acute myeloblastic leukemia (AML) allografted from their HLA-identical siblings in our single center cohort.
📊
Key Findings & Data:RESULTS: The stem cell source used was bone marrow (BM) (36.6%) or peripheral blood (PB) (63.4%).
💡
Conclusion & Impact:Estimated leukemia-free survival (LFS) and overall survival (OS) at 10 years were 43.4%±5.2% and 52.7%±4.6%, respectively.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Lösemi · miyeloid · akut

Abstract

OBJECTIVE: We retrospectively analyzed the impact of pre- and post-transplant variables on the outcome of transplanta¬tion in 145 consecutive patients with acute myeloblastic leukemia (AML) allografted from their HLA-identical siblings in our single center cohort. RESULTS: The stem cell source used was bone marrow (BM) (36.6%) or peripheral blood (PB) (63.4%). Both neutrophil and platelet engraftments were observed on the median 14th day. Engraftment was faster in the PB group than in the BM group (p<0.0001). Severe acute graft versus host disease (aGvHD) was observed in 27.9% of the patients while chronic (c)GvHD developed in 61.2%. The use of PB was associated with more severe aGvHD. Estimated leukemia-free survival (LFS) and overall survival (OS) at 10 years were 43.4%±5.2% and 52.7%±4.6%, respectively. CONCLUSION: Both in univariate and multivariate analyses for LFS and OS, remission status at transplant and the presence of aGvHD were independent risk factors.

Özet

AMAÇ: AML tanısı ile HLA-özdeş kardeş vericiden allojeneik transplantasyon yapılan 145 hastada transplantasyon öncesi ve sonrası değişkenlerin transplantasyon sonuçlarına etkisini geriye dönük olarak değerlendirdik. BULGULAR: Kullanılan kök hücre kaynağı kemik iliği (Kİ) (% 36.6) veya periferik kan (PK) (% 63.4)’ dı. Nötrofil ve trombosit engraftmanı ortanca 14.günlerdeydi. PK grubunda engraftman Kİ grubuna göre daha kısa sürede oldu (p<0.0001). Ciddi akut graft versus host hastalığı (aGvHH) hastaların % 27,9’unda gözlenirken, kronik(k) GvHH % 61,2’inde gelişti. PK kul¬lanımı daha ciddi aGvHH gelişimine neden oldu. On yıllık lösemisiz sağkalım (LSK) ve genel sağkalım (GSK) olasılığı sırayla % 43,4±% 5,2 and % 52,7±% 4.6 idi. SONUÇ: Hem tek hem de çok değişkenli istatistiksel analizde transplantasyondaki hastalık durumu ve akut GvHH gelişimi hem LSK hem de GSK üzerine etkileyen bağımsız risk faktörleri olduğu saptandı.

🔖

Cite This Article

İLHAN, O., TOPÇUOĞLU, P., ARAT, M., SOYDAN, E. A., YÜKSEL, M. K., ARSLAN, Ö., ÖZCAN, M., GÜRMAN, G., DEMİRER, T., AKAN, H., KONUK, N., UYSAL, A. (2008). Akut myeloblastik lösemide (AML) allojeneik hematopoetik kök hücre transplantasyonu (Allo-HKHT): Tek merkez deneyimi. Turkish Journal of Hematology, Cilt: 25 - Sayı: 2, 87–93. https://ajindex.com/articles/413042

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Clift RA, Buckner CD, Thomas ED, Kopecky KJ, Appelbaum FR, Tallman M, Storb R, Sanders J, Sullivan K, Banaji M. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987;2:243-58
  2. Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP, Milpied N, Attal M, Michallet M, Ifrah N, Kuentz M, Dauriac C, Bordigoni N, Gratecos N, Guilhot F, Guyotat D, Gouvernet J, Gluckman E. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxantotal body irradiation as preparative regimen: a report from the Groupe d’Etudes de la Greffe de Moelle Osseuse. Blood 1992;79:2578-82
  3. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotali B, Leoni P, Peetermans ME, Dardenne M, Vegna ML, Concetta M, Solbu G, Suciu S. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995;332:217-23
  4. Keating S, de Witte T, Suciu S, Willemze R, Hayat M, Labar B, Resegotti L, Ferrini PR, Caronia F, Dardenne M, Solbu G, Petti MC, Vegna ML, Mandelli F, Zittoun RA. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol 1998;102:1344-53
  5. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, Harrison G; Medical Research Council Adult and Paediatric Working Parties. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002;118:385-400
  6. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, De Rosa G, Belhabri A, Giustolisi R, Delarue R, Liso V, Mirto S, Leone G, Bourhis JH, Fioritoni G, Jehn U, Amadori S, Fazi P, Hagemeijer A, Willemze R. EORTC and GIMEMA Leukemia Groups. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003;102:1232-40
  7. Harousseau JL, Cahn JY, Pignon B